Unadjusted OR | 95% CI | Adjusted OR | 95% CI | P-value | |
---|---|---|---|---|---|
Adherence history: | |||||
poor at least once vs optimal | 1.34 | (0.81, 2.17) | 1.30 | (0.78, 2.10) | 0.30 |
non-response at least once vs optimal | 1.99 | (1.01, 3.63) | 1.98 | (1.00, 3.62) | 0.03 |
missing at least once vs optimal | 3.26 | (1.65, 5.96) | 3.60 | (1.80, 6.65) | <0.001 |
Pre-ART WHO disease stage | |||||
stage 2 | 1(ref) | 1(ref) | 0.8 | ||
stage 3 | 1.08 | (0.61, 2.02) | 1.02 | (0.57, 1.91) | |
stage 4 | 1.48 | (0.76, 2.92) | 1.19 | (0.60, 2.41) | |
Pre-ART CD4 cell count | |||||
0-49 | 1.69 | (0.88, 3.51) | 1.43 | (0.72, 3.07) | |
50-99 | 1.27 | (0.61, 2.77) | 1.18 | (0.55, 2.61) | |
100-149 | 1.07 | (0.49, 2.41) | 1.01 | (0.45, 2.29) | |
150-199 | 1(ref) | 1(ref) | 0.6 | ||
Pre-ART Body mass index | |||||
<20 | 1.35 | (0.82, 2.18) | 1.31 | (0.79, 2.14) | |
20-27 | 1(ref) | 1(ref) | 0.5 | ||
>27 | 1.37 | (0.59, 2.79) | 1.33 | (0.57,2.77) | |
Age at ART initiation groups | |||||
18-35 | 1(ref) | 1(ref) | 0.9 | ||
35-50 | 0.84 | (0.53, 1.35) | 0.92 | (0.57, 1.50) | |
50+ | 0.89 | (0.31, 2.09) | 1.03 | (0.35, 2.48) | |
Sex | |||||
Female vs Male | 1.23 | (0.76, 2.04) | 1.31 | (0.79, 2.22) | 0.3 |
Time since ART initiation in years | |||||
≤2 | 1(ref) | 1(ref) | 0.06 | ||
2-3 | 0.37 | (0.17, 0.73) | 0.40 | (0.18, 0.79) | |
3-4 | 0.57 | (0.30, 1.04) | 0.60 | (0.31, 1.10) | |
4-5 | 0.49 | (0.24, 0.93) | 0.47 | (0.23, 0.91) | |
>5 | 0.76 | (0.34, 1.54) | 0.65 | (0.29, 1.34) |